12:00 AM
 | 
Jun 30, 2014
 |  BC Week In Review  |  Company News  |  Other News

Selecta, Bill & Melinda Gates Foundation, NIH drug delivery, neurology, infectious news

Selecta received a $8.1 million grant from NIH’s National Institute on Drug Abuse (NIDA) to develop SEL-068, a nicotine vaccine for smoking cessation and relapse prevention. The targeted synthetic vaccine particle (tSVP) that activates immune...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >